Chemioimmunoterapia con cisplatino, epirubicina ed alfa-interferone nel melanoma in fase avanzata

Translated title of the contribution: Chemoimmunotherapy with cisplatin, epirubicin and alpha-interferon in metastatic melanoma

S. Carpano, A. Amodio, S. Bucher, P. Foggi, P. Vici, M. Rinaldi, S. Mariotti, G. Del Monte, M. Lopez

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the activity and toxicity of cisplatin (DDP), epirubicin (EPI) and interferon alfa-2a(a-IFN) in patients (pts) with metastatic melanoma. Patients and Methods: Thirty-seven pts with histologically-proven metastatic melanoma were treated with DDP 75 mg/m2 e.v. and EPI 90 mg/m2 e.v. on day 1 + α-IFN 9 MUI/die s.c. on days 4 to 8 and 18 to 22. Cycles were repeated every 4 weeks. Results: Characteristics of the patients were the following: median age 55 years (range, 24-75), median WHO performance status 1 (range, 0-2), prior chemotherapy 9, prior immunotherapy 16 (adjuvant/advanced 11/5), sites of disease: soft tissue only 10, lung 22, liver 11, bone 1, brain 3. In 35 evaluable patients we have obtained 3 complete and 10 partial responses, for an overall response rate of 37%. Dose-limiting toxicity was myelosuppression with grade (G) 4 neutropenia in 59.5% of patients and G4 thrombocytopenia in 11% of patients. Other toxicities were generally mild to moderate with nausea and vomiting in 67.5% of patients, flu-like syndrome in 78.5% and fatigue in 48.5% of the patients. Median time to response, median time to progression and survival were 3 (range, 2-6), 7 (range, 2-45+) and 10 months (range, 4-45+), respectively. Conclusion: This combination is active and well tolerated in metastatic melanoma. Toxicity was manageable and has enabled us to conduct this trial on an outpatient basis.

Translated title of the contributionChemoimmunotherapy with cisplatin, epirubicin and alpha-interferon in metastatic melanoma
Original languageItalian
Pages (from-to)109-114
Number of pages6
JournalClinica Terapeutica
Volume150
Issue number2
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Chemoimmunotherapy with cisplatin, epirubicin and alpha-interferon in metastatic melanoma'. Together they form a unique fingerprint.

  • Cite this

    Carpano, S., Amodio, A., Bucher, S., Foggi, P., Vici, P., Rinaldi, M., Mariotti, S., Del Monte, G., & Lopez, M. (1999). Chemioimmunoterapia con cisplatino, epirubicina ed alfa-interferone nel melanoma in fase avanzata. Clinica Terapeutica, 150(2), 109-114.